Full spectrum flow cytometry-powered comprehensive analysis of PBMC as biomarkers for immunotherapy in NSCLC with EGFR-TKI resistance

BACKGROUND: Clinical studies suggest that immune checkpoint inhibitor (ICI) monotherapy has limited benefits in non-small cell lung cancer (NSCLC) patients after epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) failure. However, data about efficacy of ICI plus chemotherapy remai...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juan, Chu, Xiangling, Zhao, Jing, Xie, Mengqing, Wu, Jing, Yu, Xin, Fang, Yujia, Li, Yazhou, Li, Xiyan, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364374/
https://www.ncbi.nlm.nih.gov/pubmed/37488517
http://dx.doi.org/10.1186/s12575-023-00215-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364374/
https://www.ncbi.nlm.nih.gov/pubmed/37488517
http://dx.doi.org/10.1186/s12575-023-00215-0

Ejemplares similares